article thumbnail

Maestro nets $15 million for its interactive commerce, community and engagement tools for livestreams

TechCrunch LA

Existing investors like SeventySix Capital, The Strand Partners, Stadia Ventures, Hersh Interactive Group, and Transcend Fund, as well as early Zoom employees Richard Gatchalian and Aaron Lewis, also participated. . “The third piece is a developer ecosystem,” Evans said.

Tool 315
article thumbnail

Demand Media Nets $77.2M From IPO

socalTECH

in net proceeds from the firm's IPO last week. The firm, which debuted on the NYSE as DMD, said it will use the new funding for investments in content, international expansion, working capital, product development, sales and marketing activities, general and administrative matters and capital expenditures.

.Net 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

10 Ways To Get The Capital You Need For Your Startup

Startup Professionals Musings

Find a major customer, or a complimentary business, who sees such value in your idea that they are willing to give you an advance on royalty payments to complete your development. Solicit venture capital investors. Variations on this theme include early licensing or white-labeling agreements. Join a startup incubator or accelerator.

Startup 106
article thumbnail

Prevoty Launches New Products For Java,NET

socalTECH

Los Angeles-based Prevoty , a developer of enterprise security tools, said Thursday that it has rolled out two new products, which plug into apps running on Java and.NET.

Java 100
article thumbnail

Design Therapeutics Sets IPO Offering Range

socalTECH

Carlsbad-based Design Therapeutics, a company developing treatments for serious degenerative disorders, has set an expected IPO offering range of between $18.00 The company is venture backed by SR One, Quan Capital, Cormorant Asset Management, and WestRiver Group. and $20.00 per share, the company said in a filing this week.

Design 113
article thumbnail

PharmaCyte Biotech Shifting To Nasdaq

socalTECH

Laguna Hills-based biotech developer PharmaCyte Biotech said late Monday that the company is shifting to the Nasdaq Capital Market, having been approved to list on the exchange as PMCB. The company, which currently trades OTCQB, is focused on developing cellular therapies for cancer and diabetes. Wainwright.

.Net 113
article thumbnail

Evofem Prices $50M Offering

socalTECH

San Diego-based Evofem Biosciences, which is developing biopharmaceuticals for women's contraception and related areas, says it has priced a $50M, public offering, and also will receive up to an additoinal $50M upon exercise of accompanying short-term warrant.

Pricing 113